DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Apokyn (Apomorphine Hydrochloride) - Summary

 
 



APOKYN SUMMARY

APOKYN™ (apomorphine hydrochloride, USP) is a non-ergoline dopamine agonist.

APOKYN™ (apomorphine hydrochloride injection) is indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced Parkinson's disease. APOKYN has been studied as an adjunct to other medications (see CLINICAL PHARMACOLOGY: Clinical Trials).


See all Apokyn indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Apokyn (Apomorphine)

Medical News Today: Scientists offer new view on origins of Parkinson's disease
Source: Featured Health News from Medical News Today [2016.06.24]
A new study suggests stress on the endoplasmic reticulum of cells triggers neurodegeneration in Parkinson's disease and not just failure of mitochondria.

Scientists offer new view on origins of Parkinson's disease
Source: Biology / Biochemistry News From Medical News Today [2016.06.24]
A new study suggests stress on the endoplasmic reticulum of cells triggers neurodegeneration in Parkinson's disease and not just failure of mitochondria.

Parkinson's Disease on the Rise?
Source: Medscape NeurologyHeadlines [2016.06.23]
A new study has found a significant increase in the incidence of Parkinson's over the course of 3 decades, more than doubling in men since 1976.
Medscape Medical News

Parkinson's Disease: Prevalence Seen as Rising (CME/CE)
Source: MedPage Today Neurology [2016.06.22]
(MedPage Today) -- Biggest spike seen in men 70 years of age and up

20th International Congress of Parkinson's Disease and Movement Disorders
Source: Medscape NeurologyHeadlines [2016.06.21]
Read clinically focused news coverage of key developments from MDS 2016.
Medscape Neurology

more news >>

Published Studies Related to Apokyn (Apomorphine)

Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. [2014]
may not be needed, although this has not been systematically studied... CONCLUSION: Our data suggest that trimethobenzamide helps reduce nausea/vomiting

Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson's disease. [2014]
apomorphine rescue treatment... CONCLUSIONS: Our results indicate that a 3-month use of intermittent apomorphine

Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. [2011.01]
Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain-induced cerebral activity in 25 patients with PD...

Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. [2009.05]
BACKGROUND: Motor fluctuations in patients with advanced Parkinson's disease may be successfully treated with subcutaneous apomorphine infusion or intraduodenal levodopa/carbidopa infusion. No comparative trials of these two alternatives were performed. AIMS OF THE STUDY: We present a subanalysis from a randomized crossover clinical trial where levodopa infusion as monotherapy was compared with any other combination of pharmacotherapy in fluctuating patients. Four patients used apomorphine infusion and oral levodopa in the comparator arm. The results of these four patients are presented in detail... CONCLUSIONS: Monotherapy with duodenal infusion of levodopa was more efficacious and brought greater QoL than combination therapy with apomorphine infusion in these fluctuating patients.

Apomorphine nodules in Parkinson's disease: best practice considerations. [2008.10]
Apomorphine hydrochloride infusion therapy is used by approximately 1000 people with advanced Parkinson's disease in the UK (Britannia Pharmaceuticals Ltd, 2008).

more studies >>

Clinical Trials Related to Apokyn (Apomorphine)

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) [Completed]

Treatment of Apomorphine-induced Skin Reactions: a Pilot Study [Not yet recruiting]
Skin reactions as a result of continuous subcutaneous apomorphine infusion occur frequently and interfere with the absorption of apomorphine. The histopathology of apomorphine-induced skin reactions is poorly understood. Therefore treatment options are limited and suggestive. Objective: to investigate the efficacy of four treatments including massage, dilution of apomorphine, treatment with topical hydrocortisone and pre-treatment with subcutaneous administered hydrocortisone, in Parkinson's disease patients with apomorphine-induced skin reactions.

Infusion of Apomorphine: Long-term Safety Study [Recruiting]
This is a Phase 3, multicenter, open-label, safety and efficacy study of continuous infusion apomorphine in subjects with advanced Parkinson's Disease (PD) who are unable to achieve adequate control despite optimized noninvasive therapy.

Safety/Efficacy of Tigan´┐Ż to Control Nausea/Vomiting Experienced During Apokyn´┐Ż Initiation and Treatment [Completed]
The purposes of the study are to determine: i. To assess the efficacy of Tigan« (trimethobenzamide) in preventing nausea and vomiting when initiating therapy with Apokyn« (apomorphine) ii. To determine the optimal duration for continuation of Tigan« following initiation of Apokyn┬« therapy iii. To assess the safety of Tigan┬« in combination with Apokyn┬« iv. To characterize the pharmacokinetic (PK) profile of apomorphine in subjects treated concomitantly with and without Tigan┬«

Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO) [Recruiting]
OH dependence is associated with DA receptor changes. Both, the apomorphine test and the D2Rec SPECt are usefull for monitoring DA receptor status. We aimed at studying whether DA receptor hypofunction, assessed by means of the apomorphine test and the D2Rec SPECT, is a marker of relapse in detoxified OH dependents patients.

more trials >>

Reports of Suspected Apokyn (Apomorphine) Side Effects

Fall (4)Pruritus (2)Erythema (2)Somnolence (2)Malaise (2)Overdose (2)Dyspnoea (2)Condition Aggravated (2)Atrial Fibrillation (2)Malabsorption From Injection Site (2)more >>


Page last updated: 2016-06-24

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015